‘MSD Korea excessively monitors workers, collects client info without consent’
MSD Korea used to be called one of the best workplaces in the pharmaceutical industry in Korea. However, employees’ complaints have mounted over deteriorating welfare and excessive monitoring of salespersons, according to the company’s labor union. The Korean offshoot of the U.S.-based multinational
2 drugs for enlarged prostate not different in depression risk
Two classes of the drug for enlarged prostate -- 5-alpha reductase inhibitors and alpha blockers -- showed no difference in depression risk, according to a study by the Korea Institute of Drug Safety and Risk Management. GSK’s Avodart (top), a 5-alpha reductase inhibitor for enlarged prostate, and M
Health minister asks AI-backed drug-developing support center to go bolder
The government has requested a new support center for artificial intelligence-based new drug development to picture a “daring and detailed blueprint.”Health and Welfare Minister Park Neung-hoo made the remark in the opening ceremony of the Center for AI-based New Drug Development Facilitation, at th
Korea closing in on tailored gene therapies to fight cancer
‘Precision medicine project K-Master has finished analysis on 2,000 genomic data of cancer patients’
Korea’s state-supported precision medicine project group, dubbed K-Master, has completed analyzing about 2,000 pieces of genomic data of cancer patients, the head of the group said.It started 13 clinical trials for precision medicine last year and plan to conduct seven more this year, he said.
'US sales of Truxima imminent'
Celltrion Chairman Seo Jung-jin said Wednesday that U.S. sales for Truxima, a Rituxan biosimilar which received approval from the U.S. Food and Drug Administration last year, is imminent. Celltrion Chairman Seo Jung-jin explains the company’s current position in the U.S. market and its g